Prana Biotechnology Ltd (PBT)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Prana Biotechnology Ltd (PBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013607
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prana Biotechnology Ltd (Prana Biotech) is a pharmaceutical company that develops therapeutic drugs. The company is conducting research into Huntington disease, Alzheimer’s disease, brain cancer, and other major age-related degenerative disorders. It is developing first-in-class therapies for the treatment of neurodegenerative disease. Prana Biotech develops technology platform in association with various institutions and medical institutes. The company also maintains a library of metal protein attenuating compounds that may support new therapies for neurodegenerative disease. It also conducts various clinical programs. The company collaborates with various universities for its research projects. Prana Biotech is headquartered in Melbourne, Victoria, Australia.

Prana Biotechnology Ltd (PBT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Prana Biotech Enters into Research Agreement with Takeda Pharma 10
Equity Offering 11
Prana Biotech Plans to Raise upto USD50 Million in Public Offering of Securities 11
Prana Biotech Completes Second Tranche Of Private Placement Of Shares For US$6 Million 12
Prana Biotechnology Announces Public Offering Of American Depositary Receipts For US$47.2 Million 13
Prana Biotech Completes Rights Offering Of Shares For US$2.1 Million 14
Prana Biotech Raises USD7.3 Million in Private Placement of Shares 15
Prana Biotech Completes Private Placement Of Shares For US$6 Million 16
Prana Biotech Completes Private Placement Of Shares For US$0.4 Million 17
Prana Biotech Completes Private Placement Of Shares For US$0.2 Million 18
Prana Biotech Completes Private Placement Of Ordinary Shares For US$1.3 Million 19
Prana Biotech Completes Private Placement Of US$1 Million 20
Prana Biotech Completes Private Placement Of US$6.19 Million 21
Prana Biotechnology Ltd – Key Competitors 22
Prana Biotechnology Ltd – Key Employees 23
Prana Biotechnology Ltd – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Jun 05, 2017: Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development 25
Apr 11, 2016: Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA Submission 26
Other Significant Developments 27
Dec 23, 2016: Prana Business Update 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Prana Biotechnology Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Prana Biotech Enters into Research Agreement with Takeda Pharma 10
Prana Biotech Plans to Raise upto USD50 Million in Public Offering of Securities 11
Prana Biotech Completes Second Tranche Of Private Placement Of Shares For US$6 Million 12
Prana Biotechnology Announces Public Offering Of American Depositary Receipts For US$47.2 Million 13
Prana Biotech Completes Rights Offering Of Shares For US$2.1 Million 14
Prana Biotech Raises USD7.3 Million in Private Placement of Shares 15
Prana Biotech Completes Private Placement Of Shares For US$6 Million 16
Prana Biotech Completes Private Placement Of Shares For US$0.4 Million 17
Prana Biotech Completes Private Placement Of Shares For US$0.2 Million 18
Prana Biotech Completes Private Placement Of Ordinary Shares For US$1.3 Million 19
Prana Biotech Completes Private Placement Of US$1 Million 20
Prana Biotech Completes Private Placement Of US$6.19 Million 21
Prana Biotechnology Ltd, Key Competitors 22
Prana Biotechnology Ltd, Key Employees 23

★海外企業調査レポート[Prana Biotechnology Ltd (PBT)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kier Group plc (KIE):企業の財務・戦略的SWOT分析
    Kier Group plc (KIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Genae Associates NV:医療機器:M&Aディール及び事業提携情報
    Summary Genae Associates NV (Genae Group) is a medical device CRO that offers clinical trial management services. The organization develops and commercializes investigational products and therapies that advance practices in medicine. Its services comprise clinical trial management, regulatory and sa …
  • Enel Generacion Chile SA:企業の発電所・SWOT分析2018
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • NTN Corporation (6472):企業の財務・戦略的SWOT分析
    NTN Corporation (6472) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Tokyo Electron Ltd (8035):企業の財務・戦略的SWOT分析
    Tokyo Electron Ltd (8035) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Harbin Gloria Pharmaceuticals Co Ltd (002437):製薬・医療:M&Aディール及び事業提携情報
    Summary Harbin Gloria Pharmaceuticals Co Ltd (Harbin Gloria) is a pharmaceutical company that produces and markets nutritional drugs. The company’s products include pharmaceutical drugs for treating nutrition disorders, cancer, cardiovascular diseases, antitumor medication, respiratory medication, a …
  • Ameriprise Financial, Inc. (AMP):企業の財務・戦略的SWOT分析
    Ameriprise Financial, Inc. (AMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Kuros Biosciences Ltd (KURN)-製薬・医療分野:企業M&A・提携分析
    Summary Kuros Biosciences Ltd (Kuros Biosciences) is a biotechnology company that develops products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specificall …
  • Columbia Power Corporation:企業の戦略的SWOT分析
    Columbia Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Earle M. Jorgensen Company:企業の戦略・SWOT・財務情報
    Earle M. Jorgensen Company - Strategy, SWOT and Corporate Finance Report Summary Earle M. Jorgensen Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • United Bank Of India:企業の戦略・SWOT・財務分析
    United Bank Of India - Strategy, SWOT and Corporate Finance Report Summary United Bank Of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Owen Mumford Ltd:企業の戦略的SWOT分析
    Owen Mumford Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • PT Sun Life Financial Indonesia:企業の戦略・SWOT・財務情報
    PT Sun Life Financial Indonesia - Strategy, SWOT and Corporate Finance Report Summary PT Sun Life Financial Indonesia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Aminex PLC (AEX):企業の財務・戦略的SWOT分析
    Summary Aminex PLC (Aminex) is an oil and gas company that explores, develops and produces oil and gas reserves in Africa. The company provides assets such as Valeni field and Viktorovka field in Moldova; West Esh el Mellaha-2 in Egypt; and Kiliwani North development, Nyuni exploration, and Ruvuma e …
  • Prothena Corp Plc (PRTA):企業の財務・戦略的SWOT分析
    Summary Prothena Corp Plc (Prothena) discovers and develops therapies for the treatment of neurological disorders. It is evaluating Prasinezumab (PRX002/RG7935), a monoclonal antibody targeting alpha-synuclein protein, against Parkinson’s disease and other related synucleinopathies; and PRX004, an i …
  • AmerisourceBergen Corporation:企業の戦略・SWOT・財務分析
    AmerisourceBergen Corporation - Strategy, SWOT and Corporate Finance Report Summary AmerisourceBergen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Konecranes Plc:企業のM&A・事業提携・投資動向
    Konecranes Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Konecranes Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Portland General Electric Co:企業の発電所・SWOT分析2018
    Portland General Electric Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Alexander & Baldwin Inc (ALEX):企業の財務・戦略的SWOT分析
    Alexander & Baldwin Inc (ALEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報
    Summary Voyager Therapeutics Inc (Voyager) is a clinical-stage gene therapy company that develops treatments for patients suffering from severe neurological diseases. The company provides treatment for adeno-associated virus gene therapy field by selecting, designing and manufacturing vectors. Its c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆